New concepts in drug discovery: Collateral efficacy and permissive antagonism

Nature Reviews Drug Discovery

Volumn 4, Issue 11, 2005, Pages 919-927

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); ANGIOTENSIN DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARECOLINE; CARBACHOL; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PARATHYROID HORMONE; PILOCARPINE; T 140; VINBURNINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR MECHANICS; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN BINDING; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 27844519281     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1875     Document Type: Review

References (51)

1. Kenakin, T. P. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103-109 (2002).
2. Stephenson, R. P. A modification of receptor theory Br. J. Pharmacol 11, 379-393 (1956).
3. Brady, A. E. & Limbird, L. E. G protein-coupled receptor interacting proteins: Emerging roles in localization and signal transduction. Cellular Signalling. 14, 297-309 (2002).
4. Lanier, S. M. AGS proteins, GPR motifs and the signals processed by heterotrimeric G proteins. Biol. Cell. 96, 369-372 (2004).
5. George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808-820 (2002).
6. Mack, M. et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of hiv infectivity. J. Exp. Med. 187, 1215-1224 (1998).
7. Kohout, T. A. & Lefkowitz, R. J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization Mol. Pharmacol. 63, 9-18 (2003).
8. Sneddon, W. B. et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EPB50). J. Biol. Chem. 278, 43787-43796 (2003).
9. Ferguson, S. S. G. Evolving concepts in G-protein coupled receptor endocytosis: The role in receptor desensitization and signaling. Pharmacol. Rev. 53, 1-24 (2001).
10. Roettger, B. F. et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 51, 357-362 (1997).
11. Thomas, W. G., Quian, H., Chang, C.-S. & Karnik, S. Agonist-induced phosphorylation of the angiotensin II (AT1A) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J. Biol. Chem. 275, 2893-2900 (2000).
12. Horne, W. C., Shyu, J.-F., Chakraborthy, M. & Baron, R. Signal transduction by calcitonin: Multiple ligands, receptors and signaling pathways. Trends Endocrinol. Metab. 5, 395-401 (1994).
13. Kenakin, T. P. Agonist-receptor efficacy II: Agonist-trafficking of receptor signals. Trends Pharmacol. Sci. 16, 232-238 (1995).
14. Watson, C., Chen, G., Irving, P. E., Way, J., Chen, W.-J. & Kenakin, T. P. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: Implications for the trafficking of receptor stimulus by agonists. Mol. Pharmacol. 58, 1230-1238 (2000).
15. Kenakin, T. P. Ligand-selective receptor conformations revisited: The promise and the problem. Trends Pharmacol. Sci. 24, 346-354 (2003).
16. Kenakin, T. P. Efficacy at G protein coupled receptors. Annu. Rev. Pharmacol. Toxicol. 42, 349-379 (2002).
17. Burgen, A. S. V. Conformational changes and drug action. Fed. Proc. 40, 2723-2728 (1966).
18. Kenakin, T. P. & Onaran, O. The ligand paradox between affinity and efficacy: Can you be there and not make a difference? Trends Pharmacol. Sci. 23, 275-280 (2002).
19. Hoffmann, C. et al. A FIAsH FRET approach to determine G protein-coupled receptor activation in living cells. Nature Methods 2, 171-176 (2005).
20. Gales, C. et al. Real-time monitoring of receptor/G-protein interactions in living cells. Nature Methods 2, 177-184 (2005).
21. Jakubic, J., Bacakova, L., Lisa, V., El-Fakahany, E. E. & Tucek, S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 52, 172-179 (1997).
22. Feng, Y., Broder, C. C., Kennedy, P. E. & Berger, E. A. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877 (1996).
23. Sachpatzidis, A. et al. Identification of allosteric peptide agonists of CXCR4. J. Biol. Chem. 278, 896-907 (2003).
24. Nagasaw, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638 (1996).
25. Tachibana, K. et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393, 591-594 (1998).
26. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599 (1998).
27. Demarest, J. et al. Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of 873140, a novel CCR5 receptor antagonist, in healthy subjects. 11th Conf. Retroviruses Opportunistic Infect. (San Francisco, Abs. 139, 2004).
28. Demarest, J., Shibayama S., Ferris, R., Vavro, C., StClair, M. & L. Boone. L. A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity. XV International AIDS Conf. Bangkok Intersci. Conf. on Antimicrobial Agents Chemother (Abs. WeOrA1231, 2004).
29. Lalezari, J. et al. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotheapy in HIV-infected adults. AIDS 19, 1443-1448 (2005)
30. Watson, C., Jenkinson, S., Kazmierski., W. & Kenakin, T. P. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol. Pharmacol. 67, 1268-1282 (2005).
31. Maeda. K. et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78, 8654-8662 (2004).
32. Tsamis, F. et al. Analysis of the mechanism by which the small molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type-1 entry. J. Virol. 77, 5201-5208 (2003).
33. Wu, L. et al. Interaction of the chemokine receptor CCR5 with its ligands: Multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186, 1373-1381 (1997).
34. Blanpain, C. et al. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J. Biol. Chem. 278, 5179-5187 (2003).
35. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280, 1884-1888 (1988).
36. Poignard, P., Saphire, E. O., Parren, P. W. & Burton, D. R. gp120: biologic aspects of structural features. Annu. Rev. Immunol. 19, 253-274 (2001).
37. Trkola, A. et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl Acad. Sci. USA 99, 395-400 (2002).
38. Kuhmann, S. E. et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape form small-molecule CCR inhibitor J. Virol. 78, 2790-2807 (2004).
39. Alkhatib, G., Locati, M., Kennedy, P. E., Murphy, P. M. & Berger, E. A. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G-protein signaling and importance of coreceptor down-modulation. Virology 234, 340-349 (1997).
40. Mack, M. et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J. Exp. Med. 187, 1215-1224 (1998).
41. Signoret, N., Pelchen-Mathews, A., Mack, M., Proudfoot, A. E. & Marsh, M. Endocytosis and recycling of the HIV coreceptor CCR5. J. Cell Biol. 151, 1281-1294 (2000).
42. Signoret, N. et al. Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent. Mol. Biol. Cell 16, 902-917 (2005).
43. Garzino-Demo, A. et al. Spontaneous and antigen-induced production of HIV-inhibitory β-chemokines are associated with AIDS-free status Proc. Natl Acad. Sci USA 96, 11986-11991 (1999).
44. Ullum, H. et al. Production of β-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1β are associated with a decreased risk of HIV risk progression. J. Infect. Dis. 177, 331-336 (1998).
45. Sabroe, I. et al. A small molecule antagonist of chemokine receptors CCR1 and CCR3. J. Biol. Chem. 275, 25985-25992 (2000).
46. Bartus, R. T., Dean, R. L., Beer, B. & Lippa, A. S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217, 408-417 (1982).
47. Pommier, Y. & Cherfils, J. Interfacial inhibition of macromolecular interactions: Nature's paradigm for drug discovery. Trends Pharmacol. Sci. 26, 138-145 (2005).
48. Kunkel, E. J. et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation. FASEB J. 18, 1279-1281 (2004).
49. Kunkel, E. J. et al. Rapid structure-activity and selectivity analysis of kinase inhibitors by BioMap analysis in complex human primary cell-based models. Assay Drug Dev. Technol. 2, 431-441 (2004).
50. Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187-194 (1988).
51. Black, J. W. & Leff, P. Operational models of pharmacological agonists. Proc. Roy. Soc. Lond., B, (Biol.) 220, 141-162 (1983).